Abstract
Pharmacological studies of ceftriaxone, a new semisynthetic cephalosporin, were conducted in 35 cancer patients. This antibiotic was administered in a variety of doses and schedules with no observed toxicity. Intramuscular administration of 500 mg of ceftriaxone to seven patients produced mean peak serum concentrations of 32.9 μg/ml 2.0 h after administration. The terminal serum half-life was 10.9 h. Intravenous infusion of 500 mg of ceftriaxone over 5 min to the same group of seven patients produced a mean peak concentration of the drug in serum of 83 μg/ml at the end of administration which decreased to 16.8 μg/ml at 8 h. A dose of 1 g of ceftriaxone given in identical fashion to the same group of seven patients produced mean peak concentrations in serum of 130 μg/ml at the end of administration and 17.3 μg/ml at 12 h. The mean percentages of drug recovered in urine 12 h after single intravenous doses of 500 mg and 1 g were 30 and 20%, respectively. A 1-g dose of ceftriaxone was administered every 8 h to 10 patients, and a 2-g dose was administered every 12 hours to 9 patients. Drug concentrations in serum were measured for each patient after drug administration on day 1, day 3 or 4, and day 7 or 8. The 1-g dose produced an observed mean peak concentration of 154 μg/ml and a mean terminal-phase half-life of 5.6 h on day 3 or 4. The 2-g dose produced a mean peak concentration in serum of 262 μg/ml and a terminal-phase serum half-life of 6.3 h on day 3 or 4. Continuous infusion studies were performed in nine neutropenic patients for up to 8 days by using a loading dose of 1 g over 30 min, followed by 2 g every 8 h. Mean concentrations in serum were maintained at about 135 μg/ml during the infusion period.
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Beskid G., Christenson J. G., Cleeland R., DeLorenzo W., Trown P. W. In vivo activity of ceftriaxone (Ro 13-9904), a new broad-spectrum semisynthetic cephalosporin. Antimicrob Agents Chemother. 1981 Aug;20(2):159–167. doi: 10.1128/aac.20.2.159. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Bodey G. P., Rosenbaum B. Protected environments in cancer chemotherapy: design and function of a large unit. Med Pediatr Oncol. 1981;9(1):23–34. doi: 10.1002/mpo.2950090105. [DOI] [PubMed] [Google Scholar]
- Bodey G. P., Valdivieso M., Yap B. S. The role of schedule of antibiotic therapy on the neutropenic patient. Infection. 1980;Suppl 1:75–81. doi: 10.1007/BF01644940. [DOI] [PubMed] [Google Scholar]
- Hinkle A. M., Bodey G. P. In vitro evaluation of Ro 13-9904. Antimicrob Agents Chemother. 1980 Oct;18(4):574–578. doi: 10.1128/aac.18.4.574. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Meropol N. J., Fu K. P. Antibacterial activity of ceftriaxone (Ro 13-9904), a beta-lactamase-stable cephalosporin. Antimicrob Agents Chemother. 1981 Mar;19(3):414–423. doi: 10.1128/aac.19.3.414. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Patel I. H., Chen S., Parsonnet M., Hackman M. R., Brooks M. A., Konikoff J., Kaplan S. A. Pharmacokinetics of ceftriaxone in humans. Antimicrob Agents Chemother. 1981 Nov;20(5):634–641. doi: 10.1128/aac.20.5.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Patel I. H., Weinfeld R. E., Konikoff J., Parsonnet M. Pharmacokinetics and tolerance of ceftriaxone in humans after single-dose intramuscular administration in water and lidocaine diluents. Antimicrob Agents Chemother. 1982 Jun;21(6):957–962. doi: 10.1128/aac.21.6.957. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Rolfe R. D., Finegold S. M. Comparative in vitro activity of ceftriaxone against anaerobic bacteria. Antimicrob Agents Chemother. 1982 Aug;22(2):338–341. doi: 10.1128/aac.22.2.338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Schaad U. B., Stoeckel K. Single-dose pharmacokinetics of ceftriaxone in infants and young children. Antimicrob Agents Chemother. 1982 Feb;21(2):248–253. doi: 10.1128/aac.21.2.248. [DOI] [PMC free article] [PubMed] [Google Scholar]